Outpatient Medicine Update-CV Update

Video Transcription

Video Summary

This cardiovascular update reviewed atrial fibrillation (AF), coronary artery disease, antiplatelet therapy, and lipid management, using a 76-year-old woman with symptomatic AF and rapid ventricular response as a case study. Her heart rate and breathlessness improved after adding diltiazem to her existing metoprolol.<br /><br />For AF, guidelines generally favor direct oral anticoagulants (DOACs) over warfarin, except for patients with mechanical valves or significant mitral stenosis. Apixaban appears to offer the best balance of stroke prevention and bleeding risk. Stroke and bleeding risks should be reassessed regularly, and aspirin does not replace anticoagulation for AF. Evidence supports early rhythm control and catheter ablation, particularly for patients with reduced-ejection-fraction heart failure; ablation can reduce AF progression, hospitalizations, and mortality. Whether anticoagulation can be stopped after successful ablation remains an evolving question, especially for higher-risk patients.<br /><br />For patients with AF and a recent coronary stent, guidance favors a DOAC plus a P2Y12 inhibitor, with aspirin stopped after a short period. In stable coronary disease, anticoagulation alone is generally preferred over combining it with an antiplatelet drug. Antiplatelet duration should reflect both bleeding and ischemic risk; after dual therapy, clopidogrel may be preferable to aspirin for some patients.<br /><br />The lipid discussion covered updated prevention guidance: use risk assessment to guide primary prevention, consider a one-time lipoprotein(a) test, and generally use high-intensity statins for secondary prevention. Studies suggest lower-dose statin combined with ezetimibe may be an effective alternative for some patients. The talk also highlighted evidence that potassium-enriched salt substitutes may reduce stroke, heart attack, and mortality.

Keywords

atrial fibrillation

direct oral anticoagulants

apixaban

warfarin

catheter ablation

coronary artery disease

antiplatelet therapy

P2Y12 inhibitor

lipid management

high-intensity statins

ezetimibe

lipoprotein(a)

potassium-enriched salt substitute

stroke prevention